Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer

NCT01946204 is registered in ClinicalTrials.gov with Aragon Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01946204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01946204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Lead sponsor
Aragon Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 14, 2013
Completion date
December 31, 2027
Enrollment
1,207 (actual)
Sites
379

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms